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Research
Atrazine (ATR) is the most commonly used 
herbicide in the United States, where it has 
been applied to the control of broad-leaf weeds 
in a wide range of crops since the 1960s (Mills 
1998; U.S. Environmental Protection Agency 
2003). In the European Community, ATR use 
was banned in 2004 (European Commission 
2004). The widespread application of ATR to 
agricultural systems has had a major impact 
on water and soil quality because of its mobil-
ity through eco  systems and its persistence in 
the environment (Hayes 1993; Hayes et al. 
2002b, 2006; Koskinen and Clay 1997). The 
effect of ATR on animals has been difficult to 
elucidate. Some studies of whole-animal expo-
sure have correlated low environmental con-
centrations (0.1–1.0 ppb) with alterations in 
sexual development in Xenopus laevis (Hayes 
et al. 2002a, 2002b, 2006; Withgott 2002), 
olfactory-mediated behaviors in goldfish 
(Sagolio and Trijasse 1998), and mammary 
tumors in rats (Wetzel et al. 1994). However, 
other studies have found that environmen-
tally relevant doses of ATR had little effect 
on development in Xenopus laevis and other 
animals, whereas exposure to higher doses 
resulted in gonadal abnormalities (Carr et al. 
2003; Gammon et al. 2005).
The debate over the toxicological impor-
tance of ATR has stimulated research to 
identify possible mechanisms of endocrine 
interference. Previous studies have focused 
on steroid hormone receptors and nuclear 
receptors as targets for ATR and have elimi-
nated the following receptors as targets: estro-
gen, neuronal GABA, peroxisome proliferator 
activator, retinoid-related orphan, androgen, 
and glucocorticoid (Connor et al. 1996; Devos 
et al. 2003; Hooghe et al. 2000; Shafer et al. 
1999; Tennant et al. 1994). ATR has been 
shown to inhibit the secretion of gonadotropin- 
releasing hormone from the hypothalamus 
in female rats, which leads to a reduction in 
luteinizing hormone (LH) released from the 
pituitary gland (Ashby et al. 2002). ATR has 
been reported to impair LH release in female 
rats without altering hypothalamic estrogen 
receptor function (McMullin et al. 2004), 
whereas inhibition of LH in male rats has been 
linked to reduction of testosterone (Trentacoste 
et al. 2001). Studies have suggested that 
toxic effects of ATR on the nervous system 
and on the induction of mammary tumors 
are linked to altered expression of prolactin 
(PRL) (Missale et al. 1996; O’Connor et al. 
2000; Sagrillo and Elmanoff 1998). However, 
variable effects of ATR on the hypothalamic 
control of pituitary–ovarian functions and spe-
cifically on PRL have been reported (Cooper 
et al. 2000; O’Connor et al. 2000; Stoker et al. 
1999), suggesting that ATR modulation of 
PRL may be age and sex dependent.
Effects of ATR on fruiting body develop-
ment of the filamentous fungus Sclerotinia 
sclerotiorum were reported by Casale and Hart 
(1984). We initiated research to determine 
the basis of these effects using gene expres-
sion profiles. During those studies, we 
identified a transcript [GenBank acces-
sion no. GO066061 (National Center for 
Biotechnology Information 2010)] that had 
increased levels in treated tissue and showed 
slight homology to the growth hormone–
releasing hormone receptor (GHRHR) gene 
(Fakhouri WD, Trail F, unpublished data). 
Studies of this gene are in progress. However, 
intrigued by those findings, we chose to 
examine the binding specificity of ATR to the 
GHRHR and the effects on the expression of 
its target gene, growth hormone (GH), and 
the expression of other pituitary hormonal 
balance genes.
Materials and Methods
Pituitary cell culture and treatments. All cell 
culture media components and solutions were 
obtained from Invitrogen (Carlsbad, CA) unless 
otherwise stated. All other chemi  cals were 
obtained from Sigma Chemical Co. (St. Louis, 
MO), except RU38486 (a generous gift from 
S.M. Breedlove, Michigan State University). 
We obtained post  natal day (PND) 7 male 
rats from breeder females (Sprague-Dawley; 
Charles River Labs, Wilmington, MA). Animal 
use procedures were approved by the Michigan 
State University All-University Committee on 
Animal Use and Care and followed National 
Institutes of Health guidelines (Institute of 
Laboratory Animal Resources 1996). Animals 
used in this study were treated humanely and 
with regard for alleviation of suffering. 
Pituitary glands from PND7 male rats were 
dissected into HBSS+ [88 mL sterile H2O, 
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Ba c k g r o u n d: Atrazine (ATR), a commonly used herbicide in the United States, is widely distributed 
in water and soil because of its mobility through ecosystems and its persistence in the environ  ment. 
ATR has been associated with defects in sexual development in animals, but studies on mammalian 
systems have failed to clearly identify a cellular target.
oBjectives: Our goal in this study was to identify a ligand-binding receptor for ATR in pituitary 
cells that may explain the mechanism of action at the gene expression level.
Me t h o d s : We used pituitary cells from postnatal day 7 male rats and pituitary cell lines to study 
the effect of ATR on gene expression of growth hormone (GH), luteinizing hormone (LH), and 
prolactin (PRL) at RNA and protein levels. 14C-ATR was used to determine its specific binding to 
the growth hormone–releasing hormone receptor (GHRHR). The effect of ATR on structural pro-
teins was visualized using immunofluorescent in situ staining.
re s u l t s: The treatment of rat pituitary cells with ATR, at environmentally relevant concentrations 
(1 ppb and 1 ppm), resulted in a reduction of GH expression. This effect appeared to result from the 
inhibition of GH gene transcription due to ATR binding to the GHRHR of the pituitary cells.
co n c l u s i o n s: Identification of GHRHR as the target of ATR is consistent with the myriad effects 
previously reported for ATR in mammalian systems. These findings may lead to a better under-
standing of the hazards of environmental ATR contamination and inform efforts to develop guide-
lines for establishing safe levels in water systems.
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10 mL Hank’s balanced salt solution (Ca2+ and 
Mg2+ free) 10×, 1 mL HEPES buffer (1.0 M, 
pH 7.3), 1 mL antibiotic/anti  mycotic 100× 
liquid (Sigma-Aldrich, St. Louis, MO)], and 
additional HBSS+ was added to bring the 
total volume to 4.5 mL. Trypsin was added 
to 0.28% (wt/vol), and tissue was incubated 
at 37°C for 15 min. The supernatant was dis-
carded and the tissue washed with HBSS+.   
The digestion procedure was repeated a 
second time. Cells were dissociated by 
trituration, with cell number and viability 
determined by trypan blue exclusion. Cells 
were distributed to plates with 25-mm poly-
l-lysine–coated coverslips at a density of 
300,000 cells per cover  slip. Coverslips were 
then placed in 60-mm dishes containing 4 mL 
plating medium [86 mL mini  mal essential 
medium,10 mL horse serum, 3 mL glucose 
(filter sterilized, 20%), 1 mL sodium pyruvate 
(100 mM)], and cells were allowed to adhere 
to the cover  slips for 4 hr in 5% CO2 at 37°C. 
The cover  slips were then moved into 60-mm 
dishes filled with Neurobasal+ [1 mL B-27 
supplement, 1 mL antibiotic/anti  mycotic 
100×, 125 µL l-glutamine, and filled to 
50 mL with Neurobasal A (phenol red free)]. 
For competitive binding assays, cells were not 
distributed to plates but were maintained in 
HBSS+ until used.
Cultured cells were treated with ATR, 
dexamethasone (Dex), RU38486, and/or rat 
growth hormone–releasing factor [GHRF (a 
43mer peptide); molecular weight, 5,232 Da; 
> 95% HPLC purity] to determine the com-
petitive inhibition of each compound on gene 
expression. All treatments were initiated on 
day 0 in vitro. Cultures were treated with one 
of eight individual/combinations of agents: 
DMSO (vehicle); ATR [1 ppm (4.6 µM) or 
1 ppb (4.6 nM)]; Dex (10 µM); RU38486 
(10 µM); Dex (10 µM) + ATR (1 ppm); 
RU38486 (10 µM) + ATR (1 ppm); GHRF 
[0.1 ppm (20 nM), 0.5 ppm (0.1 µM), 
1.0 ppm (0.19 µM), 2.0 ppm (0.38 µM), or 
4.0 ppm (0.76 µM); or GHRF (0.1, 0.5, 1.0, 
2.0, or 4.0 ppm) + ATR (1 ppm). For the 
combination treatments, the first agent was 
administered 30 min before the the second 
agent. All chemicals were dissolved in DMSO 
such that the final DMSO concentration in 
the treatment was < 0.5% (vol/vol).
For real-time quantitative polymerase 
chain reaction (qPCR) and competitive inhi-
bition assays, cells were harvested and rinsed 
with 0.1 M phosphate-buffered saline (PBS), 
and subsequently covered with 75 µL RIPA 
(radio  immuno  precipitation assay) buffer. Cells 
were then removed from the coverslip, along 
with the liquid, and stored at –80°C. When 
cells were harvested for ATR binding-affinity 
assays, only 1 mL HBSS+ was added to the 
dissociated cells. The trypan blue exclusion 
method was used to determine cell number 
in the 1-mL volume of HBSS+, and cells were 
counted with a hemocytometer.
Real-time qPCR analysis of gene expres-
sion. We extracted total RNA from treated 
and untreated pituitary cells. Frozen or fresh 
cells were dipped briefly in liquid nitrogen 
and macerated with a pestle in 500 µL TriZol 
reagent (Invitrogen) using fine glass beads 
(diameter, 0.1 mm). The extraction and puri-
fication steps and subsequent DNase (Roche 
Applied Science, Indianapolis, IN) treatment 
were performed according to the manufactur-
er’s directions. To screen for the presence of 
DNA contamination, we performed standard 
PCR using primers specific for each gene. The 
amount and purity of the total RNA were 
determined by spectrophotometer readings 
at 260–280 nm, and equivalent amounts 
of RNA from each treatment were used for 
the reverse transcriptase reaction using the 
Superscript III enzyme (Invitrogen). The real-
time qPCR–specific primers for each gene 
were designed according to the consensus 
cDNA sequence from GenBank (National 
Center for Biotechnology Information 2010) 
using Primer Express Software (ABI700 Prism 
Software, ABI, Foster City, CA). We used 
the following primers: for GH gene, forward 
(F), 5´-CAAAGAGTTCGAGCGTGCCTA, 
reverse (R), 5´-TGGGATGGTCTCT  GA 
GAAGCA; LH gene F, 5´-CTGT  GT  GG  AG 
CG  GG  AT  TCA, R, 5´-TGCA  GG  TG  GA 
CG  AC  ATCAAG; PRL gene, F, 5´-ACCA 
TG  CT  AT  GTCACGGCTC, R, 5´-CAGG 
TG  CT  GG  AGTTCCTCGA; tubulin gene, 
F, 5´-TACCCAGACCGCATCATGAA, R, 
5´-GAAAGGGTGGCATTATAGGGC; 
actin gene, F, 5´-ACGG  TC  AG  GT  CA  TC 
AC  TATCGG, R, 5´-TGCC  AC  AG  GA  TT 
CC  AT  AC  CC; and histone H3 gene, F, 
5´-GGTAAAGCACCCAGGAAACA, R, 
5´-ACCA  GG  CC  TG  TA  AC  GA  TGAG. Real-
time qPCR normalization and analysis were 
performed according to Huggett et al. (2005) 
and Vandesompele et al. (2002).
For each experiment, results from the 
treatment replicates were averaged, and then 
the amount of mRNA of each gene was nor-
malized to the mRNA of the histone H3 
gene. We calculated the SE of each treatment 
based on the variation among the replicates 
of each tested gene, normalized to the SE of 
histone H3 in those samples. Each biological 
experiment was repeated at least twice.
Protein levels in ATR-treated pituitary 
cell cultures. We determined protein levels   
of GH, LH, PRL, and the GHRHR in the 
AtT-20 mouse pituitary tumor cell line 
[American Type Culture Collection (ATCC), 
Manassas, VA]. Cell cultures were treated with 
one of four agents—DMSO (vehicle), Dex 
(10 µM), ATR [1 ppm (4.6 µM)], or ATR 
[1 ppb (4.6 nM)]—with three replicates for 
each treatment. In another approach to block 
adreno  cortico  tropic hormone (ACTH) and 
pituitary adenylate cyclase–activating protein 
(PACAP) receptors, we quantified protein 
levels of GH in the rat GH3 pituitary tumor 
cell line (ATCC) after treatment with 5 or 
10 µL ACTH receptor antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) at a concen-
tration of 0.2 mg/mL, 15 min before treatment 
with 1 ppm ATR. Similarly, the GH3 pitui  tary 
cell line was treated with 5 or 10 µL PACAP 
receptor antibody (Santa Cruz Biotechnology) 
at a concentration of 0.2 mg/mL and incu-
bated at 37°C for 15 min, followed by treat-
ment with 1 ppm ATR. In both pitui  tary cell 
lines, protein levels of GH were assayed 2–4 hr 
after treatment with ATR at 1 ppm and 1 ppb. 
Rabbit anti-histone anti  body was used as a 
negative control. 
After treatment, cell cultures were trans-
ferred to Eppendorf tubes and harvested by 
centrifugation at 2,000 rpm for 5 min. Cells 
were washed twice with cold PBS and then 
lysed in 400 µL RIPA buffer, 5 µL protease 
inhibitor, and 5 µL EDTA for 5 min. Lysed 
cells were sonicated for 1 min on ice, centri-
fuged for 10 min at 4°C and the super  natant 
was transferred into new vials. Equivalent 
amounts of total protein from each sample were 
used for SDS-PAGE Western blot analysis. The 
house  keeping genes β-actin and β-tubulin were 
used as loading controls. Rabbit anti-rat GH, 
anti-rat LH, and anti-mouse PRL anti  bodies 
were obtained from the National Institute of 
Diabetes and Digestive and Kidney Diseases 
National Hormone and Peptide Program. 
Rabbit anti-human GHRHR antibodies were 
purchased from Abcam (Cambridge, MA). 
Goat anti-rabbit antibodies conjugated to 
horseradish peroxidase (Bio-Rad, Hercules, 
CA) were used in our chemiluminescence 
assay. This experiment was repeated twice.
Competitive binding of 14C-ATR and 
GHRF (43mers) to pituitary cells. The bind-
ing affinity of ATR-ring-UL-14C (molecu  lar 
weight, 215.7 Da; ≥ 95% HPLC purity, 25 
mCi/mmol; Sigma Chemical Co.) to pituitary 
cells was assayed after 0.5, 1.0, 2.0, and 3.0 hr 
at 37°C. For each time point, three tubes con-
taining pituitary cells (1.5 × 107 cells/mL), 
in 500 µL HBSS, were treated with 1.0 ppm 
14C-ATR. After incubation for the indicated 
time, cultures were poured over a fiberglass 
filter disk (2 cm diameter) in a Buchner funnel 
and washed with 2 mL TCA buffer (trichlo-
roacetic acid 10% plus sodium pyrophosphate 
1%) under vacuum. The filter disks were 
transferred into separate glass vials contain-
ing 5 mL scintillation cocktail (Econo-Safe, 
Research Products International Corp., Mount 
Prospect, IL). The vials were shaken briefly 
and loaded into counting racks. The radio-
activity of each vial was measured using a 
Beckman Coulter LS6500 scintillation coun-
ter (Beckman Coulter, Brea, CA). Pituitary Fakhouri et al.
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cells not exposed to 14C-ATR were included 
as negative controls. To determine how long 
14C-ATR takes to reach saturation binding to 
the pituitary cells, we monitored the binding 
of 1.0 ppm 14C-ATR to pitui  tary cells over a 
3-hr time course. No significant increase in 
14C-ATR binding, as measured by radioactiv-
ity associated with cells, was observed after a 
0.5-hr incubation. 
To test the ability of GHRF to competi-
tively inhibit the binding of 14C-ATR, we 
simultaneously added both GHRF and 
14C-ATR to pituitary cells (in a total volume 
of 20 µL for both compounds per 500 µL cell 
culture). Competition assays were performed 
using 1.0 ppm 14C-ATR and increasing con-
centrations of GHRF (0.1–4.0 ppm). The 
cells were incubated at 37°C for 0.5 hr and 
then processed as described above. As a posi-
tive control, we included a competitive inhibi-
tion assay with unlabeled ATR and 14C-ATR. 
To determine the linear correlation between 
GHRF and ATR concentrations to the bound/
free 14C-ATR ratio, the results were analyzed 
using linear curve-fitting analysis.
Immunofluorescent labeling of actin and 
tubulin. After treatment, culture medium was 
replaced with warm fixative (4% paraformal-
dehyde with 5% sucrose in 0.1 M PBS) for 
10 min, followed by a rinse in 0.1 M PBS 
and 1 hr in 50% ethanol at 4°C. Cells were 
rinsed; then blocking solution (10% normal 
goat serum, 0.1% Triton in 0.1 M PBS) was 
added at room temperature (22–24°C) for 
0.5 hr. One of the following primary antibod-
ies was used: mouse monoclonal anti-actin 
antibody (1:1,000) or mouse mono  clonal anti- 
tubulin (β-III isoform) antibody (1:1,000; 
both antibodies from Chemicon, Temecula, 
CA). Anti  bodies were diluted in 10% nor-
mal goat serum in 0.1 M PBS; each culture 
was incubated with the primary antibody for 
2 hr at room temperature. Tissue was rinsed 
and then exposed to the secondary antibody 
(  fluorescein-conjugated goat anti-mouse 
IgG, 1:2,500; Vector, Burlingame, CA); tis-
sue was rinsed, and Vectastain Elite ABC 
reagents (Vector) were added according to 
the manufacturer’s directions. The cells on 
the coverslips were rinsed, dehydrated, and 
mounted on a coverslip using the aqueous 
PVA-DABCO anti  fading mounting medium 
(Sigma-Aldrich). Cells were visualized using an 
inverted Nikon TE2000-U microscope (Nikon, 
Melville, NY) with a Photometrics Cascade 
512B camera (Photometrics, Tucson, AZ) and 
the Metamorph imaging system (version 6.2; 
Universal Imaging, Downingtown, PA). 
Results
Quantification of gene expression. GH, LH, 
and PRL are major hormones of the anterior 
pituitary gland that are regulated by specific 
releasing hormones that bind to the corre-
sponding releasing hormone receptor in the 
pituitary gland (Childs et al. 1994a, 1999). 
We examined the effect of ATR on the expres-
sion of GH, LH, and PRL genes in cultured 
rat pituitary cells by treating cells with ATR at 
environmentally relevant levels (low, 1.0 ppb; 
high, 1.0 ppm) and monitoring transcript   
levels to detect shifts in expression.
Previous work has demonstrated that 
neonatal ATR exposure affects the sexual 
development of frogs, turning them into her-
maphrodites (having sexual characteristics of 
both males and females) (Hayes et al. 2002b; 
Kniewald et al. 2000). ATR may likewise affect 
the neuro  endocrine axis in mammals. The 
critical period for sexual differentiation of the 
rodent brain occurs between embryonic day 18 
and PND10 (Arnold and Breedlove 1985). 
Given that ATR exposure may have the poten-
tial to affect sexual differentiation of the rodent 
brain and that preliminary investigations sug-
gest that the survival of pituitary cells in cul-
ture is maximal at the end of the first postnatal 
week (Nuñez JL, personal communication), 
we cultured pituitary cells on PND7. Exposure 
of pituitary cells to 1.0 ppm ATR resulted in 
a remarkable reduction in the mRNA levels 
of genes encoding GH and LH (Figure 1). 
However, levels of PRL mRNA increased in 
the treated cells compared with controls.
To determine whether ATR effects are 
mediated through the GHRHR, we used rat 
GHRF, a 43-amino acid peptide that binds 
specifically to GHRHR (Bloch et al. 1983; 
Montero et al. 2000; Spiess et al. 1983; 
Thorner et al. 1983). Previous studies have 
shown that GHRF binds to GHRHR and 
up-regulates the expression of the GH gene in 
healthy human and rat pituitary cells (Bloch 
et al. 1983; Montero et al. 2000; Thorner et al. 
1983) with an optimal range of 1–3 µg/kg 
body weight in vivo and 0.1–10 nM in vitro 
(Thorner et al. 1983; Velicelebi et al. 1986). 
Serum levels of PRL and LH were not 
increased after administration of human GHRF 
at 1 µg/kg body weight (Thorner et al. 1983). 
We treated pituitary cells with 1.0 ppm ATR 
alone and combined with increasing levels of 
GHRF. GH expression was reduced in ATR-
treated cells compared with controls, but GH 
expression did not appear to be inhibited in 
cells treated with ATR and GHRF (Figure 2), 
suggesting that GHRF may displace ATR 
binding to the GHRHR. Contrary to expecta-
tions, GH expression was lower after treatment 
with 1 ppm GHRF compared with 0.5 ppm 
GHRF. Furthermore, GH expression was also 
slightly reduced in cells treated with ATR and 
2 ppm GHRF compared with cells treated with 
ATR and 1 ppm GHRF. One possible expla-
nation is variation in responses among different 
batches of primary pituitary cells; however, GH 
expression was two times higher in the cells 
treated with ATR and 2 ppm GHRF com-
pared with ATR alone. Homeostatic amounts 
of GH or GHRH may vary among culture 
runs. This variation could be avoided by using 
a pituitary cell line. However, cultures of cell 
lines may also result in changes that do not 
reflect innate tissue responses.
Protein levels of GH, LH, PRL, and 
GHRHR in ATR-treated pituitary cell cul-
ture. To test the effect of ATR on the final 
product of GH, LH, PRL, and GHRHR genes, 
we used Western blot analysis to detect the 
amount of proteins in pituitary cells 30 min 
Figure 1. Expression (mean ± SE) of GH, LH, and 
PRL genes in rat pituitary cells treated with DMSO 
(control) or with 1.0 ppb or 1.0 ppm ATR. Cells were 
harvested 72 hr after treatment, and gene expres-
sion was meas  ured by real-time qPCR; data were 



































Figure 2. Expression (mean ± SE) of the GH gene 
in pituitary cells 72 hr after treatment with GHRF 
alone, ATR (1 ppm) alone, or ATR combined with 
increasing concentrations of GHRF (0.1, 0.5, 1.0, or 
2.0 ppm). Treatments with vehicle (DMSO) or ATR 
alone were used as controls. Data were normalized 





































Figure 3. Protein levels of GH, LH, PRL, and GHRHR 
assayed in mouse AtT-20 pituitary cell culture 30 min 
after treatment with vehicle (DMSO; lanes 1 and 2), 
Dex (10 µM; lanes 3 and 4), ATR (1 ppm; lanes 5 
and 6), or ATR (1 ppb; lanes 7 and 8). β-Actin protein 
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after treatment. The amount of GH and LH 
protein in AtT-20 pituitary cell cultures was 
slightly reduced in cells treated with 1.0 ppm 
and 1.0 ppb ATR compared with the nega-
tive control (treated with the vehicle alone). 
In contrast, the amount of PRL was slightly 
increased in ATR-treated cells. The protein 
level of GHRHR was similar in all treatment 
groups (Figure 3).
Competitive binding of 14C-ATR and 
GHRF (43mers) to pituitary cells. Previous 
studies on GHRHR binding have evalu-
ated displacement of radio  labeled ligands 
at concentrations ranging from 30 to 80 µg   
protein/mL (or 0.2 nM) by non-radio  labeled 
substances at concentrations ranging from 
10–6 to 10–12 M (Rekasi et al. 2000; Varga 
et al. 1999). To determine whether GHRF 
displaces ATR on the cell surface, we per-
formed competitive binding studies using 
14C-radiolabeled ATR. Binding of 14C-ATR 
to pituitary cells reached saturation 0.5 hr 
after incubation [see Supplemental Material, 
Figure 1 (doi:10.1289/ehp.0900738)]. If ATR 
binds to the GHRHR, GHRF should displace 
ATR on the receptor. Therefore, we performed 
a competitive binding assay between 14C-ATR 
and GHRF (Figure 4). Pituitary cells treated 
with 14C-ATR and increasing concentrations 
of GHRF had reduced radioactivity compared 
with cells treated with 14C-ATR alone, which 
suggests that 14C-ATR and GHRF were com-
peting for the same receptor (Figure 4A,C). 
Unlabeled ATR (0.5–4.0 ppm) also displaced 
14C-ATR in a concentration-dependent   
manner (Figure 4B,D). 
Competitive effect of Dex and RU38486 
on GH expression. To further test the role 
of ATR in affecting GH expression through 
GHRHR, we treated cells with ATR, Dex, 
or RU38486, alone or combined because 
Dex and RU38486 act as an agonist and an 
antagonist, respectively, to GH expression. 
Dex stimulates the expression of the GH gene 
by increasing expression of the GHRHR gene 
in pituitary cells through down-regulation of 
somato  statin receptor–mediated inhibition of 
the GHRH protein (Tamaki et al. 1996; Xu 
et al. 1995). RU38486 reduces the expression 
of the GH gene by repressing the expression of 
the GHRHR gene as a consequence of gluco-
corticoid receptor repression (Ohyama et al. 
1998). Dex alone considerably induced GH 
expression in pituitary cells, but GH expres-
sion in response to Dex and 1.0 ppm ATR 
was comparable to expression in response 
to ATR alone (Figure 5). RU38486, which 
normally antagonizes the expression of the 
GH gene, caused enhanced repression when 
combined with ATR; however, the repression 
does not seem to be remarkably different com-
pared with RU38486 alone because of varia-
tion within the technical replicates (Figure 5). 
The results of these experiments may suggest 
that RU38486 and ATR act in concert to 
lower the expression of GH and that ATR 
can mask Dex effects. If ATR acts through 
the GHRHR, then ATR would enhance the 
effects of RU38486 and suppress the effects of 
Dex, which is what we observed.
ATR effects on tubulin and actin. In 
response to 1.0 ppm ATR, expression of the 
housekeeping genes actin and tubulin was 
reduced, as well as expression of GH and LH 
[Figure 1; see also Supplemental Material, 
Figure 2 (doi:10.1289/ehp.0900738)]. 
Therefore, to determine whether reduced gene 
expression might have resulted from cell tox-
icity or death, we used immuno  fluorescent 
staining to evaluate tubulin and actin micro-
filaments in pituitary cells treated with 1.0 ppm 
ATR. Although we observed some deteriora-
tion in filament structure (see Supplemental 
Material, Figure 3), the increase in PRL expres-
sion observed after ATR treatment (Figure 1) 
and the maintenance of relatively consistent 
levels of histone H3 expression (absolute levels 
are not shown) suggest that the cells were still 
functioning physiologically.
GH protein levels in the GH3 cell line 
after blocking ACTH and PACAP receptors. 
ACTH protein has been reported to suppress 
GH secretion in blood serum (Izumi et al. 
1985). To minimize the effect of ACTH on 
GH, we saturated rat GH3 pituitary cells 
with incremental amounts of ACTH receptor 
anti  body before applying ATR. Consistent 
with our results using the AtT-20 cell line 
(Figure 3), we observed a remarkable reduc-
tion in GH levels after treatment with ATR 
at 1 ppm and 1 ppb (Figure 6). Furthermore, 
blocking the ACTH receptor with anti  body 
did not interfere with the antagonistic effect 
of ATR on GH. We included the histone H3 
antibody as a nonspecific antibody to either 
Figure 4. Competitive binding of GHRF to pituitary cells after initial treatment with 14C-ATR for 30 min. The 
labeled pituitary cells were treated with increasing concentrations of GHRF (A) or unlabeled ATR (B). The 
correlation between GHRF (C) and ATR (D) concentrations and the bound/free 14C-ATR ratio was analyzed 
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Figure 5. Expression of the GH gene in pituitary cells 
72 hr after treatment with ATR (1 ppm), Dex (10 µM), 
RU38486 (RU; 10 µM), Dex + ATR or RU + ATR. Data 



































ATR Dex Dex + ATR RU + ATR RU
Figure 6. Levels of GH evaluated in rat GH3 pitu-
itary cell culture 2 hr after ATR treatment. Lane 1, 
DMSO; lane 2, antibody (5 µL); lane 3, antibody (10 
µL); lane 4, ATR (1 ppm); lane 5, ATR (1 ppb); lane 6, 
antibody (5 µL) and ATR (1 ppm); lane 7, antibody 
(10 µL) and ATR (1 ppm). The antibodies used were 
ACTHR (row a) and PACAP receptor (row b); tubu-
lin (row c) was used as an internal loading control. 
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ACTH receptor or GHRHR, which served as 
a negative control [see Supplemental Material, 
Figure 4 (doi:10.1289/ehp.0900738)]. 
PACAP receptor has around 60% homology 
with GHRHR. Therefore, we used a similar 
approach to block possible binding of ATR 
to the PACAP receptor in GH3 cells using 
incremental amounts of PACAP receptor anti-
body. We observed a moderate alleviation of 
the antagonistic effect of ATR on GH protein 
levels (Figure 6).
Discussion
In the present study we have identified a 
ligand-binding receptor, the GHRHR, which 
is responsive to the herbicide ATR. In a study 
on the distribution of 14C-ATR in vivo after 
lactational exposure in the Wistar rat, Stoker 
and Cooper (2007) showed that a small con-
centration of ATR was present in the anterior 
pituitary. This supports our finding that the 
pituitary gland is a target of ATR. The GHRH 
protein is produced in the hypothalamus and 
binds to the GHRHR in pituitary cells, result-
ing in the production of GH. GH regulates 
several metabolic processes in cells and dif-
ferentiated tissues, including cell growth and 
proliferation; pituitary, prostate, and adrenal 
gland sizes; and the size of accessory reproduc-
tive organs (Cohen and Radovick 2002; Mogi 
et al. 2005; Stoker et al. 2002), which may 
explain the diverse effects noted in previous 
studies. GH also stimulates the activation of 
the gonadotropin-releasing hormone receptor, 
which leads to the secretion of gonadotropins 
and LH in pituitary cells (Childs et al. 1994b, 
1999). We observed that GH and LH expres-
sion was reduced in primary cultured rat pitui-
tary cells after exposure to ATR (Figure 1). 
Furthermore, our results suggest that LH 
expression may be reduced because of reduced 
GH expression resulting from ATR-mediated 
effects on the GHRHR. We also documented 
an increase in PRL expression in pituitary cells 
treated with ATR, which might be relevant to 
the mammary tumor formation in ATR-treated 
female rats reported by Wetzel et al. (1994). 
In another study, Giusi et al. (2006) found 
that ATR affected the dimorphic expression 
patterns of somatostatin subtype2,3,5 receptor 
mRNA. Somatostatin antagonizes the stimula-
tory actions of GHRH, which leads to repres-
sion of GH in mammals (Iranmanesh et al. 
2004). Our findings suggest that increased 
somatostatin receptor expression may be sec-
ondary to an antagonistic effect of ATR on 
GHRHR. To our knowledge, this is the first 
evidence of a receptor in animals that binds the 
herbicide ATR. ATR may affect other path-
ways as well. We tested whether the effect of 
ATR on GH might also be mediated through 
the PACAP receptor. However, despite homol-
ogy in protein domain sequences between the 
PACAP receptor and GHRHR, blocking ATR 
binding to the PACAP receptor had relatively 
moderate effects on GH expression in response 
to ATR, which suggests that ATR is not a pri-
mary ligand for the PACAP receptor.
Conclusions
The results of the present study indicate that 
ATR targets the GHRHR of pituitary cells 
and that ATR-mediated inhibition of GH pro-
duction in pituitary cells results from competi-
tion between ATR and GHRF for GHRHR 
binding. To our knowledge, this is the first 
time a receptor for ATR has been identified. 
GH is a major hormone of the endocrine sys-
tem; thus, our results may help explain diverse 
effects of ATR reported by others. In addition, 
identification of GHRHR as a target of ATR 
may facilitate future studies of the effects of 
this herbicide on environmental and human 
health and inform efforts to develop guidelines 
for safe levels of ATR in water systems.
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